Florent Grange
Centre Hospitalier Universitaire de Reims · 316 works · 13,373 citations · h-index 51
Top works
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
- Blastic NK-Cell Lymphomas (Agranular CD4+CD56+ Hematodermic Neoplasms): A Review
- Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease
- Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
- Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin
- WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects
- Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas.
- Prognostic Factors in Primary Cutaneous Large B-Cell Lymphomas: A European Multicenter Study
- A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma
- Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
- Blastic NK-Cell Lymphomas (Agranular CD4+CD56+ Hematodermic Neoplasms)
- Prognostic factors in primary cutaneous lymphomas other than mycosis fungoides and the Sézary syndrome. The French Study Group on Cutaneous Lymphomas.
- Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
- Indolent CD8-positive Lymphoid Proliferation of the Ear
- Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice?
- Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients
- Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629)
- 3301 Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma
- Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas